Showing 1 - 10 of 40
Unfair intentions provoke negative reciprocity from others, making their concealment potentially beneficial. This paper explores whether people hide their unfair intentions from others and how hiding intentions is itself perceived in fairness terms. Our experimental data show a high frequency of...
Persistent link: https://www.econbiz.de/10011185621
parallel trade of heavily regulated medicines rather than a traditional source of arbitrage (e.g., price and income differences …
Persistent link: https://www.econbiz.de/10011274346
TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with three blockbusters accounting for 8 % of total pharmaceutical sale in Norway. With use of a unique natural policy experiment in Norway, this paper examines to what extent the identity of the...
Persistent link: https://www.econbiz.de/10008727300
generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …
Persistent link: https://www.econbiz.de/10010603857
-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel …
Persistent link: https://www.econbiz.de/10005406112
We study effects of direct-to-consumer advertising (DTCA) in the prescription drug market. There are two pharmaceutical firms providing horizontally differentiated (branded) drugs. Patients differ in their susceptibility to the drugs. If DTCA is allowed, this can be employed to induce...
Persistent link: https://www.econbiz.de/10005406241
We consider a therapeutic market with potentially three pharmaceutical firms. Two of the firms offer horizontally differentiated brand-name drugs. One of the brand-name drugs is a new treatment under patent protection that will be introduced if the profits are sufficient to cover the entry...
Persistent link: https://www.econbiz.de/10005406396
We study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. First, we construct a vertical...
Persistent link: https://www.econbiz.de/10008799730
TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with three blockbusters accounting for 8 per cent of total pharmaceutical sale in Norway. Novelty of the paper is to examine, with the use of a unique natural policy experiment in Norway, to what...
Persistent link: https://www.econbiz.de/10009371358
We show that ambiguity aversion increases the value of a statistical life as soon as the marginal utility of wealth is higher if alive than dead. The intuition is that ambiguity aversion has a similar effect as an increase in the perceived baseline mortality risk, and thus operates as the...
Persistent link: https://www.econbiz.de/10005406403